港股異動 | 昊海生物科技漲逾3% 延長股份鎖定期
格隆匯4月8日丨昊海生物科技(6826.HK)昨日收漲7.59%,今日續漲,現報30.15港元,漲3.79%,暫成交954萬港元,最新總市值53億港元。昊海生物科技上週五(3日)晚間發公告稱,截至2020年4月3日收市,公司股票已連續20個交易日收盤價低於本次發行價格89.23元/股,觸發承諾的履行條件。公司實際控制人、控股股東、董事、高級管理人員和核心技術人員持有限售流通股及本次延長限售股鎖定期。此外據悉,根據聯交所最新權益披露資料顯示,昊海生物科技於4月1日遭大摩在場內以每股均價31.0356港元減持H股好倉約13.47萬股,涉資約418.07萬港元。減持後,其持H股好倉比例由7.03%降至6.69%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.